These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36577551)

  • 1. STAR-TREC: An International Three-arm Multicentre, Partially Randomised Controlled Trial Incorporating an External Pilot.
    Bach SP
    Clin Oncol (R Coll Radiol); 2023 Feb; 35(2):e107-e109. PubMed ID: 36577551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC)? Protocol for the international, multicentre, rolling phase II/III partially randomized patient preference trial evaluating long-course concurrent chemoradiotherapy versus short-course radiotherapy organ preservation approaches.
    Bach SP;
    Colorectal Dis; 2022 May; 24(5):639-651. PubMed ID: 35114057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.
    Bach SP; Gilbert A; Brock K; Korsgen S; Geh I; Hill J; Gill T; Hainsworth P; Tutton MG; Khan J; Robinson J; Steward M; Cunningham C; Levy B; Beveridge A; Handley K; Kaur M; Marchevsky N; Magill L; Russell A; Quirke P; West NP; Sebag-Montefiore D;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):92-105. PubMed ID: 33308452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we
    Rombouts AJM; Al-Najami I; Abbott NL; Appelt A; Baatrup G; Bach S; Bhangu A; Garm Spindler KL; Gray R; Handley K; Kaur M; Kerkhof E; Kronborg CJ; Magill L; Marijnen CAM; Nagtegaal ID; Nyvang L; Peters FP; Pfeiffer P; Punt C; Quirke P; Sebag-Montefiore D; Teo M; West N; de Wilt JHW;
    BMJ Open; 2017 Dec; 7(12):e019474. PubMed ID: 29288190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality-of-life outcomes in older patients with early-stage rectal cancer receiving organ-preserving treatment with hypofractionated short-course radiotherapy followed by transanal endoscopic microsurgery (TREC): non-randomised registry of patients unsuitable for total mesorectal excision.
    Gilbert A; Homer V; Brock K; Korsgen S; Geh I; Hill J; Gill T; Hainsworth P; Tutton M; Khan J; Robinson J; Steward M; Cunningham C; Kaur M; Magill L; Russell A; Quirke P; West NP; Sebag-Montefiore D; Bach SP;
    Lancet Healthy Longev; 2022 Dec; 3(12):e825-e838. PubMed ID: 36403589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).
    Serra-Aracil X; Pericay C; Badia-Closa J; Golda T; Biondo S; Hernández P; Targarona E; Borda-Arrizabalaga N; Reina A; Delgado S; Vallribera F; Caro A; Gallego-Plazas J; Pascual M; Álvarez-Laso C; Guadalajara-Labajo HG; Mora-Lopez L
    Ann Oncol; 2023 Jan; 34(1):78-90. PubMed ID: 36220461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of total mesorectal excision (TME) surgery following dose-escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma (OPERA) trial, a European multicentre phase 3 randomised trial (NCT02505750).
    Sun Myint A; Rao C; Barbet N; Thamphya B; Pace-Loscos T; Schiappa R; Magné N; Martel-Lafay I; Mineur L; Deberne M; Zilli T; Dhadda A; Gerard JP
    Colorectal Dis; 2023 Nov; 25(11):2160-2169. PubMed ID: 37837240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimisation of Organ Preservation treatment strategies in patients with rectal cancer with a good clinical response after neoadjuvant (chemo)radiotherapy: Additional contact X-ray brachytherapy versus eXtending the observation period and local excision (OPAXX) - protocol for two multicentre, parallel, single-arm, phase II studies.
    Geubels BM; van Triest B; Peters FP; Maas M; Beets GL; Marijnen CAM; Custers PA; Rutten HJT; Theuws JCM; Verrijssen AE; Cnossen JS; Burger JWA; Grotenhuis BA
    BMJ Open; 2023 Dec; 13(12):e076866. PubMed ID: 38159950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage Surgery With Organ Preservation for Patients With Local Regrowth After Watch and Wait: Is It Still Possible?
    Fernandez LM; Figueiredo NL; Habr-Gama A; São Julião GP; Vieira P; Vailati BB; Nasir I; Parés O; Santiago I; Castillo-Martin M; Carvalho C; Parvaiz A; Perez RO
    Dis Colon Rectum; 2020 Aug; 63(8):1053-1062. PubMed ID: 32692070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing neoadjuvant therapy followed by local excision to total mesorectal excision in the treatment of early stage rectal cancer: a systematic review and meta-analysis of randomised clinical trials.
    Lynch P; Ryan OK; Donnelly M; Ryan ÉJ; Davey MG; Reynolds IS; Creavin B; Hanly A; Kennelly R; Martin ST; Winter DC
    Int J Colorectal Dis; 2023 Nov; 38(1):263. PubMed ID: 37924372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 13. Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy.
    Jimenez-Rodriguez RM; Quezada-Diaz F; Hameed I; Kalabin A; Patil S; Smith JJ; Garcia-Aguilar J
    Dis Colon Rectum; 2021 Dec; 64(12):1463-1470. PubMed ID: 34508014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-inferiority multicenter prospective randomized controlled study of rectal cancer T
    Serra-Aracil X; Pericay C; Golda T; Mora L; Targarona E; Delgado S; Reina A; Vallribera F; Enriquez-Navascues JM; Serra-Pla S; Garcia-Pacheco JC;
    Int J Colorectal Dis; 2018 Feb; 33(2):241-249. PubMed ID: 29234923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selected stage IV rectal cancer patients managed by the watch-and-wait approach after pelvic radiotherapy: a good alternative to total mesorectal excision surgery?
    Custers PA; Hupkens BJP; Grotenhuis BA; Kuhlmann KFD; Breukink SO; Beets GL; Melenhorst J;
    Colorectal Dis; 2022 Apr; 24(4):401-410. PubMed ID: 35060263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial.
    Rullier E; Vendrely V; Asselineau J; Rouanet P; Tuech JJ; Valverde A; de Chaisemartin C; Rivoire M; Trilling B; Jafari M; Portier G; Meunier B; Sieleznieff I; Bertrand M; Marchal F; Dubois A; Pocard M; Rullier A; Smith D; Frulio N; Frison E; Denost Q
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):465-474. PubMed ID: 32043980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Patients With Local Regrowth After Nonoperative Management of Rectal Cancer After Neoadjuvant Chemoradiotherapy.
    Cotti GC; Pandini RV; Braghiroli OFM; Nahas CSR; Bustamante-Lopez LA; Marques CFS; Imperiale AR; Ribeiro U; Salvajoli B; Hoff PM; Nahas SC
    Dis Colon Rectum; 2022 Mar; 65(3):333-339. PubMed ID: 34775415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
    Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
    BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
    Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
    Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.